{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:34:09Z","timestamp":1760060049477,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: The global population of individuals aged \u2265 80 years is rapidly growing, leading to an increasing incidence of cancer diagnoses in this age group. While stereotactic body radiotherapy (SBRT) has proven effective in treating pulmonary oligometastases, patients over 80 remain underrepresented in clinical analyses. This study aimed to evaluate clinical outcomes and toxicity of SBRT for pulmonary oligometastases in octogenarians. Methods: This retrospective, single-centre analysis included 34 patients aged \u2265 80 years treated with SBRT for histologically confirmed pulmonary oligometastases between 2010 and 2024. Results: A total of 46 pulmonary metastases were treated with curative intent using fractionation schemes of 3 \u00d7 15 Gy, 6 \u00d7 8 Gy, or 10 \u00d7 6 Gy. Median biologically effective dose (BED10) was 112.5 Gy. Follow-up included regular CT imaging and toxicity assessment according to CTCAE. With a median follow-up of 22.6 months, 1-, 2-, and 3-year local control (LC) rates were 95.2%, 95.2%, and 90.2%, respectively. Median overall survival (OS) was 46.6 months, with 1-, 2-, and 3-year OS rates of 78.4%, 71.4%, and 59.5%. Progression-free survival (PFS) at 1, 2, and 3 years was 63.4%, 51.6%, and 47.3%, respectively. No grade \u2265 3 toxicities were observed. Grade 2 pneumonitis and dermatitis occurred in 2.9% each and were well managed. Asymptomatic rib fractures were detected in 5.9% of patients. No significant predictors for LC, PFS, or OS were identified in univariate analysis. Conclusions: SBRT for pulmonary oligometastases in patients \u2265 80 years is feasible, safe, and effective. High local control, favourable cancer-specific survival, and minimal toxicity support its use as a curative-intent treatment in this growing patient population. These findings contribute important site- and age-specific evidence and support the inclusion of very elderly patients in future prospective SBRT trials.<\/jats:p>","DOI":"10.3390\/cancers17152512","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:55:37Z","timestamp":1753872937000},"page":"2512","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SBRT in the Very Elderly: A Viable Option for Pulmonary Oligometastases?"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1711-1604","authenticated-orcid":false,"given":"Samuel M.","family":"Vorbach","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinhard","family":"Nevinny-Stickel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Ganswindt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-5316","authenticated-orcid":false,"given":"Thomas","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(20)30677-2","article-title":"Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: A forecasting analysis for the global burden of disease study","volume":"396","author":"Vollset","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102716","DOI":"10.1016\/j.canep.2024.102716","article-title":"Updated cancer burden in oldest old: A population-based study using 2022 Globocan estimates","volume":"95","author":"Shah","year":"2025","journal-title":"Cancer Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","article-title":"Planning for tomorrow: Global cancer incidence and the role of prevention 2020\u20132070","volume":"18","author":"Soerjomataram","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","article-title":"Cancer as a disease of old age: Changing mutational and microenvironmental landscapes","volume":"122","author":"Laconi","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.33232","article-title":"Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050","volume":"148","author":"Pilleron","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_6","first-page":"78","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jamaoncol.2019.2055","article-title":"Factors associated with age disparities among cancer clinical trial participants","volume":"5","author":"Ludmir","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jgo.2019.07.017","article-title":"Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists","volume":"11","author":"Sedrak","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jgo.2019.11.001","article-title":"Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials","volume":"11","author":"Ludmir","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jgo.2021.02.003","article-title":"Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study","volume":"12","author":"Tang","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Patel, R.R., Parisi, R., Verma, V., Kouzy, R., Jaoude, J.A., Lin, T.A., Fuller, C.D., VanderWalde, N.A., Jagsi, R., and Smith, B.D. (2022). Association between prior malignancy exclusion criteria and age disparities in cancer clinical trials. Cancers, 14.","DOI":"10.3390\/cancers14041048"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11912-025-01638-6","article-title":"Epidemiology of cancer in older adults: A systematic review of age-related differences in solid malignancies treatment","volume":"27","author":"Bastiaannet","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.21037\/jtd-22-239","article-title":"Impact of the extent of lung resection on postoperative outcomes of pulmonary metastasectomy for colorectal cancer metastases: An exploratory systematic review","volume":"14","author":"Prisciandaro","year":"2022","journal-title":"J. Thorac. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.21037\/jtd.2020.04.28","article-title":"The epidemiology and biology of pulmonary metastases","volume":"13","author":"Gerull","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, H., Stoltzfus, K.C., Lehrer, E.J., Horn, S.R., Siva, S., Trifiletti, D.M., Meng, M.-B., Verma, V., Louie, A.V., and Zaorsky, N.G. (2021). The epidemiology of lung metastases. Front. Med., 8.","DOI":"10.3389\/fmed.2021.723396"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/PPO.0000000000000439","article-title":"Oligometastatic disease and local therapies: A medical oncology perspective","volume":"26","author":"Hafez","year":"2020","journal-title":"Cancer J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrclinonc.2009.188","article-title":"Stereotactic body radiation therapy: A novel treatment modality","volume":"7","author":"Lo","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vorbach, S.M., Mangesius, J., Dejaco, D., Seppi, T., Santer, M., Nedden, S.Z., Sarcletti, M.P., Pointner, M.J., Hart, T.J., and Riechelmann, H. (2023). Survival, treatment outcome, and safety of multiple and repeated courses of stereotactic body radiotherapy for pulmonary oligometastases of head and neck squamous cell carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15215253"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (sabr-comet): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (sabr-comet): Extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djs285","article-title":"Use of geriatric assessment for older adults in the oncology setting: A systematic review","volume":"104","author":"Puts","year":"2012","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40520-018-0937-6","article-title":"Oligometastatic cancer in elderly patients: The \"Blitzkrieg\" Radiotherapy approach: Sbrt in oligometastatic elderly patients","volume":"31","author":"Lancia","year":"2019","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20150111","DOI":"10.1259\/bjr.20150111","article-title":"The role of stereotactic body radiation therapy (sbrt) in the treatment of oligometastatic disease in the elderly","volume":"88","author":"Scorsetti","year":"2015","journal-title":"Br. J. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10585-021-10122-x","article-title":"Sbrt for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity","volume":"38","author":"Cuccia","year":"2021","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: What we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: A safety and efficacy trial (sunset)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical percist: A simplified guide to pet response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2512\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:46Z","timestamp":1760033926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":32,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17152512"],"URL":"https:\/\/doi.org\/10.3390\/cancers17152512","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}